Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatment

The SARS-CoV-2 main protease (3CLpro) is one of the promising therapeutic targets for the treatment of COVID-19. Nirmatrelvir is the first 3CLpro inhibitor authorized for treatment of COVID-19 patients at high risk of hospitalization. We recently reported on the in vitro selection of SARS-CoV-2 3CLp...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelnabi, Rana, Jochmans, Dirk, Donckers, Kim, Trüeb, Bettina, Ebert, Nadine, Weynand, Birgit, Thiel, Volker, Neyts, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101821/
https://www.ncbi.nlm.nih.gov/pubmed/37059708
http://dx.doi.org/10.1038/s41467-023-37773-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101821/
https://www.ncbi.nlm.nih.gov/pubmed/37059708
http://dx.doi.org/10.1038/s41467-023-37773-6

Ejemplares similares